AB237730

Anti-SLAMF7/CS1 抗体 [CAL7]

Anti-SLAMF7/CS1 antibody [CAL7]

20ul selling size
BOND RX™ Validated
RabMAb
Recombinant
詳細を見る

Be the first to review this product! Submit a review

(2 Publications)

Rabbit Recombinant Monoclonal SLAMF7/CS1 antibody. Suitable for IP, WB, IHC-P and reacts with Human samples. Cited in 2 publications.

別名を表示する

CD319, CS1, UNQ576/PRO1138, SLAMF7, SLAM family member 7, CD2 subset 1, CD2-like receptor-activating cytotoxic cells, Membrane protein FOAP-12, Novel Ly9, Protein 19A, CRACC

7 Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SLAMF7/CS1 antibody [CAL7] (AB237730)

IHC-P

Lab

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SLAMF7/CS1 antibody [CAL7] (AB237730)

Immunohistochemical analysis of paraffin-embedded human multiple myeloma tissue labelling SLAMF7/CS1 with ab237730 at 1/800 dilution for 15 minutes at room temperature, followed by ready to use Goat Anti-Rabbit IgG H&L (HRP). Mainly membranous staining on the human multiple myeloma is observed. Counterstained with Hematoxylin. The immunostaining was performed on a Leica Biosystems BOND® RX instrument.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is a ready to use Goat Anti-Rabbit IgG H&L (HRP).

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SLAMF7/CS1 antibody [CAL7] (AB237730)

Formalin-fixed, paraffin-embedded multiple myeloma (Lambda, left panel) and SLAMF7 Knock-in AD-293 cells (Positive control, right panel) stained for SLAMF7/CS1 using ab237730 at 0.1 μg/ml dilution in immunohistochemical analysis.

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SLAMF7/CS1 antibody [CAL7] (AB237730)

Formalin-fixed, paraffin-embedded OPM2 xenograft (Postive control, left panel) and NCI-N87 xenograft (Negative control, right) tissue stained for SLAMF7/CS1 using ab237730 at 0.1 μg/ml dilution in immunohistochemical analysis.

IHC-P

Lab

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SLAMF7/CS1 antibody [CAL7] (AB237730)

Immunohistochemical analysis of paraffin-embedded human tonsil tissue labelling SLAMF7/CS1 with ab237730 at 1/800 dilution for 15 minutes at room temperature, followed by ready to use Goat Anti-Rabbit IgG H&L (HRP). Positive staining on human tonsil is observed. Counterstained with Hematoxylin. The immunostaining was performed on a Leica Biosystems BOND® RX instrument.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is a ready to use Goat Anti-Rabbit IgG H&L (HRP).

Lab

Immunoprecipitation - Anti-SLAMF7/CS1 antibody [CAL7] (AB237730)

SLAMF7/CS1 was immunoprecipitated from 0.35mg of IM-9 (human multiple myeloma B Lymphoblast) whole cell lysate with ab237730 at 1/30 dilution. Western blot was performed from the immunoprecipitated using ab237730 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366) was used as secondary antibody at 1/5000 dilution.

Lane 1 : IM-9 (human multiple myeloma B Lymphoblast) whole cell lysate 10μg (Input)

Lane 2 : ab237730 IP in IM-9 lysate

Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab237730 in IM-9 whole cell lysate

Blocking/diluting buffer and concentration : 5% NFDM/TBST

The expression profile observed is consistent with what has been described in the literature (PMID : 18451245; 11698418; 25312647), with the bands greater than 37 kDa predicted to be glycosylated SLAMF7/CS1.

All lanes:

Immunoprecipitation - Anti-SLAMF7/CS1 antibody [CAL7] (ab237730)

Predicted band size: 37 kDa

Observed band size: 37 kDa

false

Exposure time: 10s

Lab

Immunoprecipitation - Anti-SLAMF7/CS1 antibody [CAL7] (AB237730)

SLAMF7/CS1 was immunoprecipitated from 0.35mg of Human tonsil lysate with ab237730 at 1/30 dilution. Western blot was performed from the immunoprecipitated using ab237730 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366) was used as secondary antibody at 1/5000 dilution.

Lane 1 : Human tonsil lysate 10μg (Input)

Lane 2 : ab237730 IP in Human tonsil lysate

Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab237730 in Human tonsil lysate

Blocking/Diluting buffer and concentration : 5% NFDM/TBST

All lanes:

Immunoprecipitation - Anti-SLAMF7/CS1 antibody [CAL7] (ab237730)

Predicted band size: 37 kDa

false

Lab

Western blot - Anti-SLAMF7/CS1 antibody [CAL7] (AB237730)

Blocking/Diluting buffer and concentration : 5% NFDM/TBST

Exposure time :
Lane 1 : 3 min
Lane 2 : 1min

All lanes:

Western blot - Anti-SLAMF7/CS1 antibody [CAL7] (ab237730) at 1/1000 dilution

All lanes:

IM-9 (human multiple myeloma B Lymphoblast) whole cell lysate at 20 µg

Secondary

Lane 1:

Western blot - VeriBlot for IP Detection Reagent (HRP) (<a href='/products/reagents/veriblot-for-ip-detection-reagent-hrp-ab131366'>ab131366</a>) at 1/5000 dilution

Lane 2:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 37 kDa

false

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

CAL7

アイソタイプ

IgG

キャリアフリー

交差種

Human

アプリケーション

WB, IP, IHC-P

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30", "IP-species-notes": "", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "0.1 µg/mL", "IHCP-species-notes": " Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol." } } }

style

left-column

製品の詳細

(aka clone 43H1L46)

style

left-column

出荷温度及び保存条件

製品の状態

Liquid

精製方法

Affinity purification Protein A

精製に関する特記事項

Purity >99%

バッファー組成

pH: 7.5 Preservative: 0.05% Sodium azide Constituents: PBS

出荷温度

Conditional Ambient

短期保存期間

1-2 weeks

短期保存温度

+4°C

長期保存温度

-20°C

分注に関する情報

Upon delivery aliquot

保管に関する情報

Avoid freeze / thaw cycle

style

left-column

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

SLAMF7 also known as CS1 is a glycoprotein with a mass of approximately 70 kDa. This protein localizes on the surface of immune cells mainly on natural killer (NK) cells certain subsets of T cells and mature dendritic cells. It does not express in resting B cells but can be induced upon activation. CS1 plays a role in immune modulation by facilitating cell-to-cell interactions and activating various signaling pathways that enable immune responses.

Biological function summary

SLAMF7/CS1 modulates immune functions by engaging in interactions with other cell surface receptors. It often operates in the context of hematopoietic cells integrating signals that influence cell proliferation differentiation and survival. It does not require an associated adaptor molecule like most of the SLAM family members as it signals through its ability to recruit EAT-2. The CS1 protein modulates pathways related to immune cell activation and control making it an important player in the regulation of immune responses.

Pathways

CS1 participates prominently in immune signaling pathways where it interacts with proteins such as SAP and EAT-2. It is particularly involved in the immunoregulatory interactions contributing to NK cell-mediated cytotoxicity and modulation of T-cell responses. These interactions illustrate CS1's role in the modulation of immune responses positioning it within the broader network of immune signaling pathways important for maintaining immune homeostasis and defense mechanisms.

SLAMF7/CS1 shows key relevance in multiple myeloma and systemic lupus erythematosus (SLE). In multiple myeloma CS1 presents an overexpression and serves as a therapeutic target; its relationship with CD38 another important marker illustrates the potential for targeted therapies. In SLE improper signaling involving CS1 can contribute to the dysregulation of immune responses. Overall the intricate interactions of CS1 with other proteins highlight its significance in disease pathology and therapeutic potential.

style

left-column

style

left-column

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

ターゲットの情報

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway (PubMed : 11698418). Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K (PubMed : 16339536). In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Also acts inhibitory in T-cells (By similarity). May play a role in lymphocyte adhesion (PubMed : 11802771). In LPS-activated monocytes negatively regulates production of pro-inflammatory cytokines (PubMed : 23695528).. Isoform 3 does not mediate any NK cell activation.

See full target information SLAMF7

style

left-column

文献 (2)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in immunology 16:1656242 PubMed40895577

2025

PD-1 and LAG-3 were optimal combination of immune checkpoints for predicting poor clinical outcomes of patients with ovarian cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Yifan Wu,Cunte Chen,Yingwen Cui,Ruoyao Zou,Yaoxiang Yang,Fengjie Sun,Yanzi Du,Peipei Wang

Leukemia 35:1073-1086 PubMed32826957

2020

SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2.

Applications

Unspecified application

Species

Unspecified reactive species

Lisa von Wenserski,Christoph Schultheiß,Sarah Bolz,Simon Schliffke,Donjete Simnica,Edith Willscher,Helwe Gerull,Gerrit Wolters-Eisfeld,Kristoffer Riecken,Boris Fehse,Marcus Altfeld,Peter Nollau,Mascha Binder

View all publications

style

left-column

style

left-column

style

right-column

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。

保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-SLAMF7/CS1 抗体 [CAL7]

Anti-SLAMF7/CS1 antibody [CAL7]

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SLAMF7/CS1 antibody [CAL7] (AB237730)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SLAMF7/CS1 antibody [CAL7] (AB237730)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SLAMF7/CS1 antibody [CAL7] (AB237730)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SLAMF7/CS1 antibody [CAL7] (AB237730)

Immunoprecipitation - Anti-SLAMF7/CS1 antibody [CAL7] (AB237730)

Immunoprecipitation - Anti-SLAMF7/CS1 antibody [CAL7] (AB237730)

Western blot - Anti-SLAMF7/CS1 antibody [CAL7] (AB237730)

関連する標識済み抗体及び組成の異なる製品 (1)

Key facts

宿主種

クローン性

クローン番号

アイソタイプ

キャリアフリー

交差種

アプリケーション

免疫原

代替製品

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

組合せ製品

Assay Kits

Primary Antibodies

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity data

製品の詳細

出荷温度及び保存条件

製品の状態

精製方法

精製に関する特記事項

バッファー組成

出荷温度

短期保存期間

短期保存温度

長期保存温度

分注に関する情報

保管に関する情報

補足情報

Biological function summary

Pathways

製品プロトコール

ターゲットの情報

文献 (2)

Abcam product promise